Current Trends and Future Approaches in Small-Molecule Therapeutics for COVID-19

Author(s): Mark Laws, Yasmin M. Surani, Md. Mahbub Hasan, Yiyuan Chen, Peiqin Jin, Taha Al-Adhami, Madiha Chowdhury, Aqeel Imran, Ioannis Psaltis, Shirin Jamshidi, Kazi S. Nahar, Khondaker Miraz Rahman*

Journal Name: Current Medicinal Chemistry

Volume 28 , Issue 19 , 2021


  Journal Home
Translate in Chinese
Become EABM
Become Reviewer
Call for Editor

Abstract:

The novel coronavirus (SARS-CoV-2) pandemic has created a global public health emergency. The pandemic is causing substantial morbidity, mortality and significant economic loss. Currently, no approved treatments for COVID-19 are available, and it is likely to takes at least 12-18 months to develop a new vaccine. Therefore, there is an urgent need to find new therapeutics that can be progressed to clinical development as soon as possible. Repurposing regulatory agency-approved drugs and experimental drugs with known safety profiles can provide important repositories of compounds that can be fast-tracked to clinical development. Globally, over 500 clinical trials involving repurposed drugs have been registered, and over 150 have been initiated, including some backed by the World Health Organisation (WHO). This review is intended as a guide to research into small-molecule therapies to treat COVID-19; it discusses the SARS-CoV-2 infection cycle and identifies promising viral therapeutic targets, reports on a number of promising pre-approved small-molecule drugs with reference to over 150 clinical trials worldwide, and offers a perspective on the future of the field.

Keywords: COVID-19, SARS-CoV-2, coronavirus, drug discovery, small-molecule therapeutics, clinical trials.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 28
ISSUE: 19
Year: 2021
Published on: 21 July, 2020
Page: [3803 - 3824]
Pages: 22
DOI: 10.2174/0929867327666200721161840
Price: $65

Article Metrics

PDF: 231